Published in J Pathol on October 01, 2002
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology (2011) 3.14
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J (2005) 2.03
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer (2010) 1.85
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene (2011) 1.42
ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer (2011) 1.30
ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood (2006) 1.27
Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol (2007) 1.26
ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics (2009) 1.26
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol (2011) 1.21
New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther (2007) 1.18
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J (2014) 1.17
Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol (2006) 1.09
Breast cancer, side population cells and ABCG2 expression. Cancer Lett (2012) 1.07
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol (2007) 1.03
Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. Pharm Res (2012) 1.02
ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle (2009) 1.01
ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. Diagn Pathol (2011) 1.01
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One (2011) 1.00
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res (2008) 0.97
Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells. Xenobiotica (2012) 0.97
Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol (2006) 0.94
Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol (2012) 0.89
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen. Int J Mol Sci (2014) 0.88
Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol (2014) 0.87
The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol (2007) 0.87
Insights into Chemoresistance of Prostate Cancer. Int J Biol Sci (2015) 0.86
Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations. PLoS One (2012) 0.84
Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J Cancer Res Clin Oncol (2010) 0.84
Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.84
Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm (2010) 0.84
Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function. Mol Med (2014) 0.82
A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. Oncotarget (2015) 0.82
Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer. World J Gastroenterol (2013) 0.81
Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance. Mol Pharmacol (2011) 0.81
Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br J Cancer (2003) 0.81
Gene therapy in pancreatic cancer. World J Gastroenterol (2014) 0.81
Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics. PLoS One (2012) 0.80
Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol (2010) 0.80
A role for ABCG2 beyond drug transport: Regulation of autophagy. Autophagy (2016) 0.78
BCRP protein levels do not differ regionally in adult human livers, but decline in the elderly. Chem Biol Interact (2015) 0.77
Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast. Oncol Lett (2016) 0.76
Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases. Anticancer Agents Med Chem (2016) 0.76
ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma. BMC Cancer (2017) 0.75
ABCG2 in peptic ulcer: gene expression and mutation analysis. J Appl Genet (2015) 0.75
Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue. Sci Rep (2016) 0.75
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. Cancer Chemother Pharmacol (2014) 0.75
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol (2009) 3.72
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47
Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. Hum Mol Genet (2005) 2.36
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed (2010) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology (2007) 2.11
Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.08
Photodynamic therapy in oncology. Oncologist (2006) 2.04
Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis (2003) 1.93
Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol (2004) 1.93
Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 1.90
MRP6 (ABCC6) detection in normal human tissues and tumors. Lab Invest (2002) 1.79
Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood (2011) 1.76
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 1.66
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res (2006) 1.65
Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol (2009) 1.61
Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol (2006) 1.60
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci (2005) 1.59
Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol (2011) 1.55
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol (2010) 1.53
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res (2004) 1.51
Drug interactions in oncology. Lancet Oncol (2004) 1.49
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol (2003) 1.49
Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol (2002) 1.49
Evidence for subcomplexes in the Fanconi anemia pathway. Blood (2006) 1.43
Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist (2006) 1.43
Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene (2003) 1.39
Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn Ther (2007) 1.39
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer (2005) 1.39
ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37
Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci (2006) 1.36
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther (2008) 1.36
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer (2004) 1.35
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol (2010) 1.34
CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer (2007) 1.31
Clinical experience with aurora kinase inhibitors: a review. Oncologist (2009) 1.31
Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol (2005) 1.29
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.27
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet (2006) 1.26
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol (2010) 1.25
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res (2007) 1.24
Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicant-induced injury. Toxicol Sci (2005) 1.24
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res (2008) 1.24
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist (2005) 1.24
Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.24
Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist (2007) 1.23
Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat (2008) 1.21
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood (2002) 1.21
Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol (2006) 1.21
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res (2002) 1.21
Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm (2008) 1.21
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19
Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem (2004) 1.19
Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest (2002) 1.19
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol (2003) 1.19
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother (2008) 1.18
Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia (2004) 1.17
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res (2003) 1.17
The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother (2005) 1.17
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist (2008) 1.17
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res (2006) 1.17
Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther (2009) 1.16
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis. Eur J Immunol (2008) 1.15
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res (2004) 1.14
Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther (2002) 1.14
Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res (2007) 1.14
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol (2003) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia (2005) 1.12
Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom (2009) 1.12
Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res (2007) 1.12
Dendritic cells: biology of the skin. Contact Dermatitis (2009) 1.11
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther (2008) 1.11
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs (2008) 1.10
Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer (2002) 1.10
Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metab Rev (2007) 1.10